Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  aprepitant
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-14 of 14 for your search:
Start Over
Effect of Neurokinin-1 Receptor (NK1R) Antagonism on Pruritus in Patients With Sezary Syndrome
Phase: Phase IV
Type: Supportive care
Status: Active
Age: 18 to 80
Sponsor: Other
Protocol IDs: 110806, NCT01625455
Self-control Trial to Evaluate the Role of Aprepitant in the Prophylaxis of Post-lumbar-punture-headache (PLPH)
Phase: Phase IV
Type: Diagnostic, Supportive care
Status: Approved-not yet active
Age: 16 to 80
Sponsor: Other
Protocol IDs: PLPH, NCT02347878
Efficacy and Safety of Aprepitant in Subjects With Multiple Myeloma During and After High-dose Chemotherapy
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: EmNa (2001-004956-38), EudraCT-No: 2004-004956-38, NCT00571168
Ramosetron, Aprepitant and Dexamethasone Versus Ondansetron, Aprepitant and Dexamethasone
Phase: Phase III
Type: Supportive care
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: ROAD, NCT01536691
Efficacy of Aprepitant (Emend®) in Children
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 20 and under
Sponsor: Other
Protocol IDs: 0413, NCT01661335
Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: A221301, NCI-2014-00446, U10CA031946, NCT02116530
Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung Cancers
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: ACINV, NCT02161991
Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Fudan BR2014-15, NCT02336750
Aprepitant as Antiemetic Prophylaxis in Patients With Acute Myeloid Leukemia Undergoing Induction Chemotherapy
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AML-11-001, NCT01334086
Emend and Ondansetron Compared to Ondansetron Alone to Prevent CINV in Glioma Patients Receiving Temozolomide
Phase: Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: Pro00031206, NCT01450826
Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy
Phase: Phase II
Type: Supportive care
Status: Approved-not yet active
Age: 18 to less than 80
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: ZYTOP1502, NCT02445872
Study of Aprepitant / Fosaprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting (CINV) in Colorectal Cancer Patients - SENRI Trial
Phase: No phase specified
Type: Supportive care, Treatment
Status: Active
Age: 20 and over
Sponsor: Other
Protocol IDs: SENRI, NCT01344304
Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP
Phase: No phase specified
Type: Supportive care
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: ALLG SC03, ACTRN12611001269921, NCT01843868
A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung Cancer
Phase: No phase specified
Type: Natural history/Epidemiology, Supportive care
Status: Active
Age: 20 to 79
Sponsor: Other
Protocol IDs: 24-20, NCT02364804
Start Over